Data_Sheet_1_Prevalence and severity of anxiety and depression in Chinese patients with breast cancer: a systematic review and meta-analysis.pdf

ContextAnxiety/depression in breast cancer (BC) is common around the world, and Chinese BC patients should not be ignored. The prevalence of anxiety and depression among BC patients are various in different regions of China, but no clear summarization has been made.PurposeThis meta-analysis aimed to evaluate the prevalence and severity of anxiety and depression among breast cancer (BC) patients in China.MethodsA literature search on PubMed, Web of Science, Embase, CINAHL, Scopus, PsycINFO, Cochrane database library, CNKI, Wanfang, and SinoMed was conducted up to 29 December 2021. The effect size (ES) or standard mean difference (SMD) and the corresponding 95% confidence intervals (CIs) for the prevalence and severity of anxiety/depression were calculated using the STATA 12.0 software.ResultsA total of 63 identified studies were included, containing a total of 53,513 Chinese women confirmed breast cancer. The results showed a high pooled prevalence of anxiety (38%, 95% CI, 27–50%, I2 = 99.4%, p < 0.001) and depression (38%, 95% CI, 33–44%, I2 = 99.2%, p < 0.001) among Chinese BC patients. Moreover, both anxiety (SMD = 0.30, 95% CI, 0.08–0.53, I2 = 91.6%, p < 0.001) and depression (SMD = 0.25, 95% CI, −0.05–0.55, I2 = 95.3%, p < 0.001) in BC patients were more serious than those in healthy controls, but not significantly different from patients with other diseases. Specifically, among the six regions included, the prevalence of anxiety and depression were both the highest in Northeast China, obviously superior than the second-highest region.ConclusionThe study showed high levels of anxiety and depression among BC patients in China, especially those in the northeast. Clinicians and researchers should pay attention to the psychological problems of patients with breast cancer and regard it as one of the important prognostic outcomes of patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/index.php, PROSPERO: CRD42020151752.

全球范围内，乳腺癌（BC）患者的焦虑与抑郁情绪普遍存在，而中国乳腺癌患者亦不容忽视。在中国不同地区，乳腺癌患者的焦虑与抑郁发病率存在差异，然而尚未形成明确的总结。研究目的本项荟萃分析旨在评估中国乳腺癌患者焦虑与抑郁的发病率和严重程度。研究方法对PubMed、Web of Science、Embase、CINAHL、Scopus、PsycINFO、Cochrane数据库图书馆、CNKI、万方、SinoMed等数据库进行了文献检索，截止至2021年12月29日。采用STATA 12.0软件计算了焦虑/抑郁发病率和严重程度的效果量（ES）或标准均数差（SMD）及其相应的95%置信区间（CI）。研究结果共纳入63项研究，涉及53,513名确诊为乳腺癌的中国女性。结果显示，中国乳腺癌患者中焦虑（38%，95% CI，27–50%，I2 = 99.4%，p < 0.001）和抑郁（38%，95% CI，33–44%，I2 = 99.2%，p < 0.001）的合并发病率较高。此外，乳腺癌患者的焦虑（SMD = 0.30，95% CI，0.08–0.53，I2 = 91.6%，p < 0.001）和抑郁（SMD = 0.25，95% CI，−0.05–0.55，I2 = 95.3%，p < 0.001）程度均较健康对照组更为严重，但与患有其他疾病的患者相比并无显著差异。具体而言，在包括的六个地区中，焦虑和抑郁的发病率均以中国东北地区最高，显著高于其他地区。研究结论本研究表明，中国乳腺癌患者中焦虑和抑郁水平较高，尤其是东北地区。临床医生和研究人员应关注乳腺癌患者的心理问题，并将其视为患者预后的重要指标之一。系统综述注册信息https://www.crd.york.ac.uk/prospero/index.php，PROSPERO：CRD42020151752。